Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases

Utilizing its proprietary technology, Immunovant aims to create monoclonal antibodies that target specific pathways involved in these conditions, with the goal of providing safer and more effective treatment options. The company's research and development efforts are centered on addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from autoimmune disorders. Through its commitment to scientific advancement and patient care, Immunovant actively works to bring novel treatments to the market.